In the Claims

1.–29. (Canceled)

30. (Currently Amended) A non-human animal model of neovascularization, **wherein said non-human animal model is produced by subretinal or intravitreal delivery of a viral gene delivery vector comprising a nucleic acid encoding an angiogenic factor into an eye of the animal, wherein delivery of the vector provides for production of the angiogenic factor in the eye and induction of neovascularization** ~~of the eye, comprising an animal having an angiogenic transgene in the eye~~.

31. (Original) The non-human animal model according to claim 30 wherein said neovacularization is retinal neovascularization.

32. (Original) The non-human animal model according to claim 30 wherein said neovacularization is choroidal neovascularization.

33. (Original) The non-human animal model according to claim 30 wherein said animal is a mouse or rat.

34. (Currently Amended) The non-human animal model according to claim 30 wherein said angiogenic **factor** ~~transgene~~ is **vascular endothelial growth factor** (VEGF).

35. (Canceled)

36. - 41. (Canceled)

42. (Currently Amended) A method for **evaluating** ~~determining~~ the ability of an anti-angiogenic factor to **prevent or** inhibit neovascularization of **an** ~~the~~ eye **in a non-human animal model, the method** comprising:

(a) administering **an anti-angiogenic factor** to ~~an~~ **the eye of the non-human** animal model according to any of claims 30 to **34 and 45** ~~35 an anti-angiogenic factor~~, and

(b) determining the ability of said anti-angiogenic factor to **prevent or** inhibit neovascularization of **said** ~~the~~ eye..

43. (Original) The method according to claim 42 wherein said anti-angiogenic factor is administered subretinally.

44. (Original) The method according to claim 42 wherein said anti-angiogenic factor is administered intravitreally.

45. (New) The method according to claim 30 wherein said gene delivery vector is rAV or rAAV.

46. (New) The method according to claim 30, wherein the vector is delivered subretinally.

47. (New) The method according to claim 46, wherein the angiogenic factor is vascular endothelial growth factor (VEGF).

48. (New) The method according to claim 30, wherein the vector is delivered intravitreally.

49. (New) The method according to claim 48, wherein the angiogenic factor is vascular endothelial growth factor (VEGF).